• 1
    USRDS. Excerpts from United States Renal Data System. Annual Data Report. Causes of death. Am J Kidney Dis 1999; 34 (Suppl. 1): S87S102.
  • 2
    National Center for Health Statistics. Worktable GMWK290. Death rates for 72 selected causes by 10-year age groups, race, and sex: United States, 1979–97. Hyattsville, MD 20782–2003: National Center for Health Statistics,Division of Data Services, 1999 .
  • 3
    Aker S, Ivens K, Grabensee B, Heering P. Cardiovascular risk factors and diseases after renal transplantation. Int Urol Nephrol 1998; 30: 777788.
  • 4
    Kasiske BL. Risk factors for accelerated atherosclerosis in renal transplant recipients. Am J Med 1988; 84: 985992.
  • 5
    Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7: 158165.
  • 6
    Levey AS, Beto JA, Coronado BE et al. Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853906.
  • 7
    Deierhoi MH, Vincenti F, Filo RS, for the FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977983.
  • 8
    Hjelmesaeth J, Hartmann A, Kofstad J et al. Glucose intolerance after renal transplantation depends upon prednisolone dose and recipient age. Transplantation 1997; 64: 979983.
  • 9
    Hricik DE, Bartucci MR, Moir EJ, Mayes JT, Schulak JA, Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51: 374377.
  • 10
    Chapman JR, Marcen R, Arias M, Raine AEG, Dunnill MS, Morris PJ. Hypertension after renal transplantation: a comparison of cyclosporine and conventional immunosuppression. Transplantation 1987; 43: 860864.
  • 11
    Forslund T, Hannonen P, Reitamo S, Fyhrquist F. Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels. J Intern Med 1995; 238: 7175.
  • 12
    Sutherland F, Burgess E, Klassen J, Buckle S, Paul LC. Post-transplant conversion from cyclosporin to azathioprine: effect on cardiovascular risk profile. Transpl Int 1993; 6: 129132.
  • 13
    Hollander AAMJ, Hene RJ, Hermans JO, Van Es LA, Van Der Woude FJ. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: a randomized study. J Am Soc Nephrol 1997; 8: 294301.
  • 14
    Hansen JM, Fogh-Andersen N, Christensen NJ, Strandgaard S. Cyclosporine-induced hypertension and decline in renal function in healthy volunteers. J Hypertens 1997; 15: 319326.
  • 15
    Textor SC, Canzanello VJ, Taler SJ et al. Cyclosporine-induced hypertension after transplantation. Mayo Clin Proc 1994; 60: 11821193.
  • 16
    Kahan BD, for The Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicentre study. Lancet 2000; 356: 194202.
  • 17
    MacDonald AS, for the Rapamune Global Study Group. A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001; 71: 271280.
  • 18
    Pescovitz MD, Vanrenterghem Y, Neylan J, for the Rapamune Study Group. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999; 68: 15261532.
  • 19
    Groth CG, Bckman L, Morales JM et al, for the Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin) -based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Transplantation 1999; 67: 10361042.
  • 20
    Kreis H, Cisterne JM, Land W et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 12521260.
  • 21
    Brattstrom C, Wilczek H, Tyden G, Bottiger Y, Sawe J, Groth CG. Hyperlipidemia in renal transplant recipients treated with sirolimus (rapamycin). Transplantation 1998; 65: 12721274.
  • 22
    Anderson KM, Odell PM, Wilson PW, Kannel WB. Cardiovascular disease risk profiles. Am Heart J 1991; 121: 293298.
  • 23
    Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 30153023.
  • 24
    Tobert JA, Letter. N Engl J Med 1988; 318: 48.
  • 25
    Florijn KW, Chang PC, Van Der Woude FJ, Van Bockel JH, Van Saase JLCM. Long-term cardiovascular morbidity and mortality in autosomal dominant polycystic kidney disease patients after renal transplantation. Transplantation 1994; 57: 7381.
  • 26
    Aakhus S, Dahl K, Wideroe TE. Hyperlipidaemia in renal transplant patients. J Intern Med 1996; 239: 407415.
  • 27
    Hricik DE, Bartucci MR, Mayes JT, Schulak JA. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients. Transplantation 1992; 54: 868871.
  • 28
    Lopez-Miranda J, Perez-Jimenez F, Torres A et al. Effect of cyclosporin on plasma lipoproteins in bone marrow transplantation patients. Clin Biochem 1992; 25: 379386.
  • 29
    Dimeny E, Tufveson G, Lithell H, Larsson E, Siegbahn A, Fellstrom B. The influence of pretransplant lipoprotein abnormalities on the early results of renal transplantation. Eur J Clin Invest 1993; 23: 572579.
  • 30
    Ingulli E, Tejani A, Markell M. The beneficial effects of steroid withdrawal on blood pressure and lipid profile in children posttransplantation in the cyclosporine era. Transplantation 1993; 55: 10291033.
  • 31
    Ballantyne CM, Podet EJ, Patsch WP et al. Effects of cyclosporine therapy on plasma lipoprotein levels. JAMA 1989; 262: 5356.
  • 32
    Apanay DC, Neylan JF, Ragab MS, Sgoutas DS. Cyclosporine increases the oxidizability of low-density lipoproteins in renal transplant recipients. Transplantation 1994; 58: 663669.
  • 33
    Varghese Z, Fernando RL, Turakhia G et al. Oxidizability of low-density lipoproteins from Neoral and tacrolimus-treated renal transplant patients. Transplant Proc 1998; 30: 20432046.
  • 34
    Arnadottir M, Hultberg B, Vladov V, Nilsson-Ehle P, Thysell H. Hyperhomocysteinemia in cyclosporine-treated renal transplant recipients. Transplantation 1996; 61: 509512.
  • 35
    Arnadottir M, Hultberg B, Wahlberg J, Fellstrom B, Dimeny E. Serum total homocysteine concentration before and after renal transplantation. Kidney Int 1998; 54: 13801384.DOI: 10.1046/j.1523-1755.1998.00112.x
  • 36
    Law MR, Wald NJ, Wu T, Hackshaw A, Bailey A. Systematic underestimation of association between serum cholesterol concentration and ischaemic heart disease in observational studies: data from the BUPA study. BMJ 1994; 308: 363366.
  • 37
    Williams R, Bhopal R, Hunt K. Coronary risk in a British Punjabi population. comparative profile of non-biochemical factors. Int J Epidemiol 1994; 23: 2837.
  • 38
    Pugh RN, Hossain MM, Malik M, El Mugamer IT, White MA. Arabian Peninsula men tend to insulin resistance and cardiovascular risk seen in South Asians. Trop Med Int Health 1998; 3: 8994.
  • 39
    Seedat YK, Mayet FG. Risk factors leading to coronary heart disease among the black, Indian and white peoples of Durban. J Hum Hypertens 1996; 10 (Suppl. 3): S93S94.
  • 40
    Wilson PWF, Abbott RD. D'Agostino RB Jr, Silbershatz H, Rodriguez BL, Curb JD. Prediction of coronary heart disease in Japanese-American men [abstract]. Circulation 1998; 98 (Suppl. I): I323.
  • 41
    Keys A, Menotti A, Aravanis C et al. The seven countries study: 2,289 deaths in 15 years. Prev Med 1984; 13: 141154.